stockrow
Friday 6 November 2026
Export PCRX’s income statement to Excel — free account
Pacira BioSciences, Inc.
PCRX Healthcare Drug Manufacturers Specialty & Generic
Pacira BioSciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $726.4 million, up 3.63% from fiscal 2024.
- Revenue
- −1.59%
- EPS
- +500.0%
- Free cash flow
- −18.5%
- Total debt
- −37.4%
Quarter to September 2026, against a year earlier
36.44
0.04
+0.11%
Follow PCRX
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
172.53 | 188.33 | 72.49 | 26.37 |
P/S ratio |
1.59 | 1.24 | 1.34 | 1.34 | |
P/FCF ratio |
8.44 | 6.89 | 5.58 | 5.91 | |
P/Operating CF |
26.40 | 35.61 | 17.42 | 19.94 | |
P/B ratio |
1.66 | 1.40 | 1.49 | 1.40 | |
Price to Tangible BV |
3.78 | 3.26 | 2.73 | 2.38 | |
EV/Sales |
2.05 | 1.74 | 1.76 | 1.71 | |
EV/EBITDA |
13.76 | 11.21 | 12.77 | 12.32 | |
EV/Operating CF |
9.80 | 9.02 | 7.01 | 7.17 | |
EV/FCF |
10.90 | 9.66 | 7.33 | 7.51 | |
Quick Ratio |
3.01 | 3.01 | 3.14 | 3.32 | |
Current Ratio |
4.54 | 4.73 | 5.04 | 4.68 | |
Net Debt/EBITDA |
6.92 | 5.86 | 4.10 | 0.00 | |
Debt/Assets |
29.42% | 30.42% | 29.19% | 0.00% | |
Debt/Equity |
0.54 | 0.56 | 0.54 | 0.00 | |
Asset Turnover |
0.52 | 0.53 | 0.54 | 0.59 | |
Operating CF/Net income |
26.69 | 8.81 | 12.35 | 1.76 | |
Capex/Depreciation |
(0.01) | (0.13) | (0.06) | 0.00 | |
Interest Coverage |
0.60 | 1.87 | 1.18 | 7.72 | |
Research and Development Expense of Revenue |
19.20% | 15.83% | 15.72% | 15.10% | |
Selling, General and Administrative Expense of Revenue |
51.61% | 52.96% | 47.72% | 47.46% | |
Intangible Assets out of Total Assets |
0.31 | 0.31 | 0.25 | 0.24 | |
Share Based Compensation of Revenue |
6.86% | 7.63% | 7.77% | 6.69% | |
Graham Net Nets |
(0.02) | (0.04) | 0.04 | 0.10 | |
Graham Number |
7.25 | 6.61 | 11.58 | 19.54 | |
Earnings Yield |
0.58% | 0.53% | 1.38% | 3.79% | |
Free Cash Flow Yield |
11.85% | 14.51% | 17.93% | 16.92% | |
Revenue per Share |
4.42 | 4.38 | 4.88 | 4.43 | |
Operating CF per Share |
0.98 | 0.63 | 1.46 | 1.26 | |
Capex per Share |
0.00 | (0.07) | (0.03) | (0.09) | |
Free Cash Flow per Share |
0.98 | 0.57 | 1.42 | 1.17 | |
Cash per Share |
5.35 | 5.00 | 6.36 | 7.41 | |
Shareholders Equity per Share |
15.55 | 16.16 | 17.03 | 17.87 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
15.55 | 16.16 | 17.03 | 17.87 | |
Free Cash Flow |
43.47 | 22.96 | 56.12 | 46.45 | |
Working Capital |
427.38 | 406.17 | 493.20 | 464.13 | |
Capital Expenditures |
(0.22) | (2.72) | (1.34) | (3.62) | |
Net Current Asset Value |
(23.83) | (39.68) | 43.21 | 99.91 | |
EV/EBIT |
77.62 | 53.20 | 66.21 | 35.45 | |
Capex to Sales |
0.00 | 0.02 | 0.01 | 0.02 | |
Price to Operating Income |
60.10 | 37.94 | 50.38 | 27.91 | |
| Other line items | |||||
Average Receivables |
118.69 | 115.19 | 123.39 | 119.08 | |
Average Payables |
17.14 | 18.59 | 23.82 | 17.60 | |
Average Inventory |
139.07 | 142.06 | 141.37 | 143.59 | |
Average Assets |
1,409.22 | 1,397.60 | 1,390.62 | 1,250.11 | |
Average Common Equity |
735.73 | 726.22 | 714.87 | 719.77 |
Columns are period end dates · fundamentals updated 5 Nov 2026